AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

The Zacks Accident and Health Insurance industry is expected to benefit from an increase in underwriting exposure. Aflac ...

The latest Market Talks covering Financial Services. Exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ...

Schwab U.S. Mid-Cap ETF's low fees and diversification aren't enough to outweigh its underperformance. Click here to find out ...